CD70: An emerging target in cancer immunotherapy
Julie Jacobs(Argenx (Belgium)), Patrick Pauwels(University of Antwerp), Karen Zwaenepoel(University of Antwerp), Sylvie Rottey(Ghent University Hospital), Vanessa Deschoolmeester(University of Antwerp), Evelien Smits(University of Antwerp), Filip Lardon(University of Antwerp), Christian Rolfo(Icahn School of Medicine at Mount Sinai), Karen Silence(Ablynx (Belgium))
Cited by 225
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642